Repertoire Immune Medicines inks $189m Series B

Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this